Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Uplizna
Inebilizumab, sold under the brand name Uplizna, is a monoclonal antibody medication used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 (AQP4) antibody positive. It targets CD19, a protein expressed on B cells, a type of white blood cell implicated in the autoimmune attack on the central nervous system seen in NMOSD. By depleting these B cells, inebilizumab aims to reduce the inflammatory response responsible for the debilitating symptoms of NMOSD, such as vision loss, muscle weakness, and pain.
Inebilizumab is used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 (AQP4) antibody positive.
Outcome:
Reduced vaccine efficacy, increased risk of infection
Mechanism:
Immunosuppression
Outcome:
Increased risk of bleeding
Mechanism:
Platelet inhibition
Outcome:
May increase risk of infection
Mechanism:
Immunosuppression
Most likely new formulation: Subcutaneous injection (2025, 75% confidence)
Based on current clinical trial data and post-market surveillance, inebilizumab is expected to maintain its current approval status with a 90% likelihood over the next 5 years.
Monoclonal Antibody, Immunosuppressant
Immunoglobulin G4 (IgG4) monoclonal antibody